The answer so far
Early controlled studies of ARA-290 reported some promising changes in symptoms or nerve-related measurements, but results differed by study and outcome. They involved small, selected groups for a short time. They do not establish that the peptide repairs nerves or treats all neuropathies.135
On this page
What question were researchers asking?
The studies asked whether a particular investigational peptide could change markers or symptoms in specific people, mainly those with sarcoidosis-associated small-fibre problems or type 2 diabetes and painful extremities. Those conditions and outcomes are not interchangeable. Start with what ARA-290 is and why it was developed.35
- SymptomsQuestionnaires record what participants say they feel.
- Corneal nerve fibresA specialised eye image measures a marker, not pain directly.
- Daily functionWalking or other activity measures ask a different question.
- SafetyShort trials record events but cannot establish all long-term risks.
What did the early sarcoidosis studies find?
A 2012 placebo-controlled pilot enrolled 22 people with sarcoidosis and small-fibre symptoms for four weeks. A symptom-screening score improved more in the peptide group than in the placebo group. A 2013 controlled study in 38 people reported improvements in a symptom list and examined several measures including fine nerve fibres. These are human results, not merely animal data, but small, short studies cannot establish that every person benefits or that a response persists.12
What did the 64-person study measure?
The 2017 randomised study assigned 64 people with sarcoidosis-associated painful small-fibre loss to three peptide groups or placebo. Its main outcome was the change after 28 days in the area occupied by nerve fibres in images of the cornea. One peptide group had a statistically significant difference from placebo; the other two did not. Multiple small groups make estimates uncertain, and this marker is not itself a pain score. The company developing the peptide sponsored the study.34
Did the same study prove less pain?
Pain scores improved in all groups, including placebo. In the study’s moderate-to-severe pain subgroup, the reported comparison for the middle peptide group was not statistically significant. That does not prove there is no effect, but it does not establish a reliable pain benefit either. A corneal image, a questionnaire and the ability to carry out daily tasks each answer a different question.3
What about the diabetes study?
A separate trial enrolled 49 people with type 2 diabetes and painful extremities; 48 were analysed after one withdrawal. It followed four weeks of treatment with another four weeks of observation. The authors reported a difference on one neuropathic symptom questionnaire, while another symptom score improved similarly in both groups. Some measures of blood sugar also changed, but a short, small study cannot establish lasting diabetes control or nerve repair. Several authors were officers or shareholders of the developer.5
What did the safety records report?
The EU registry for the 64-person trial records serious adverse events in three of 46 people analysed on the peptide and none of 16 on placebo; allocation was unverifiable for two people. One event was assessed as related in the registry. These records matter, but the study is too small to establish a risk rate or say that every event was caused by the peptide. In the separate diabetes study, a participant died after an infection and heart attack; the study safety committee judged the death unrelated. Neither study can settle long-term safety.45
How should I read a “nerve regeneration” claim?
Ask which nerve fibres were measured, in whom, how long a change lasted and whether pain, sensation and daily function improved compared with a control. A positive cell or image result does not automatically mean a damaged nerve has recovered useful function. Two unrelated animal papers on the peptide were later retracted; that does not mean the human trials above were retracted, but it is a reason to check the specific source rather than a seller’s citation list. A certificate of analysis does not establish a product’s clinical benefit; see how to read one.367
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathyMolecular Medicine / PubMed · Randomised placebo-controlled pilot
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber lossMolecular Medicine / PubMed Central · Randomised placebo-controlled study
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic PainInvestigative Ophthalmology & Visual Science · Randomised placebo-controlled phase 2b trial
- EU clinical trial results: ARA 290 in sarcoidosis small fibre neuropathy, 2013-003016-45EU Clinical Trials Register · Official trial registry and results
- ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 DiabetesMolecular Medicine · Randomised placebo-controlled study
- Retraction: A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in miceBritish Journal of Pharmacology / PubMed · Retraction notice
- Retraction notice for an ARA 290 rat kidney injury studyMolecular Medicine / PubMed · Retraction notice